Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Clin Ther. 2009 Dec;31(12):2940-52. doi: 10.1016/j.clinthera.2009.12.019.
The aim of this study was to investigate the market uptake of biologic and small-molecule-targeted oncology drugs in Europe.
Targeted oncology drugs that were used in one of the selected European countries before the end of 2007 were eligible for inclusion in the analysis. The following European countries were included: Austria, Croatia, France, Germany, Hungary, Italy, Slovenia, and the United Kingdom. Monetary market uptake of targeted oncology drugs was assessed by using sales data (in euros) obtained from 2 large data- bases for the period 1997-2007. Market uptake was assessed in terms of expenditures for specific drugs in euros per capita and in market shares.
The monetary market uptake of targeted oncology drugs had an exponential growth from 1997 to 2007 in all comparison countries and reached 40% of the total oncology drug market in 2007. Although the various European countries allocate substantially different amounts of resources per capita for oncology drugs, the share of expenditures attributed to targeted oncology drugs did not differ substantially among the countries. Biologic molecules were used in clinical practice before the small-molecule-targeted oncology drugs. Targeted oncology drugs that were introduced first to clinical practice in most of the comparison countries (ie, rituximab, trastuzumab, imatinib mesylate) maintained the leading positions on the market throughout the period of the analysis. In 2007, approximately 25% of all expenditures for oncology drugs were attributed to biologic oncology drugs, and approximately 15% were spent on small-molecule-targeted oncology drugs.
Expenditures on targeted oncology drugs have been increasing exponentially in Europe throughout the past decade and have reached a 40% share of the oncology drug market. As of 2007, the market share of biologic oncology drugs was higher than the market share of small-molecule-targeted oncology drugs.
本研究旨在考察欧洲生物制剂和小分子靶向肿瘤药物的市场占有率。
纳入分析的靶向肿瘤药物需满足以下条件：在 2007 年底前已在所选欧洲国家之一中使用。纳入的欧洲国家包括：奥地利、克罗地亚、法国、德国、匈牙利、意大利、斯洛文尼亚和英国。使用从两个大型数据库获取的 1997 年至 2007 年期间的销售数据（欧元）评估靶向肿瘤药物的货币市场占有率。从特定药物的人均支出（欧元）和市场份额两方面评估市场占有率。
在所有比较国家中，靶向肿瘤药物的货币市场占有率从 1997 年至 2007 年呈指数级增长，2007 年达到肿瘤药物总市场的 40%。尽管各国人均分配的肿瘤药物资源数量有很大差异，但靶向肿瘤药物支出份额在各国之间差异不大。生物制剂先于小分子靶向肿瘤药物应用于临床实践。在大多数比较国家（即利妥昔单抗、曲妥珠单抗、甲磺酸伊马替尼）中首先引入临床实践的靶向肿瘤药物在整个分析期间一直保持领先地位。2007 年，约 25%的肿瘤药物支出归因于生物肿瘤药物，约 15%的支出用于小分子靶向肿瘤药物。
在过去十年中，欧洲靶向肿瘤药物的支出呈指数级增长，已达到肿瘤药物市场的 40%。截至 2007 年，生物肿瘤药物的市场份额高于小分子靶向肿瘤药物。
